GoodRx Holdings (GDRX) Receivables - Net (2019 - 2026)

GoodRx Holdings has disclosed Receivables - Net across 8 years of filings, most recently posting $232.7 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $232.7 million, up 45.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $232.7 million (up 45.34% YoY), and the FY2025 annual result was $235.7 million, up 61.54% from the prior year.
• Receivables - Net came in at $232.7 million for Q1 2026 at GoodRx Holdings, down from $235.7 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $235.7 million in Q4 2025 to a low of $116.4 million in Q1 2023.
• The 5-year median for Receivables - Net is $143.6 million (2023), against an average of $152.6 million.
• Across the five-year window, Receivables - Net jumped 65.7% in 2022 and slipped 5.55% in 2023, its largest moves.
• GoodRx Holdings' Receivables - Net stood at $117.1 million in 2022, then gained by 22.59% to $143.6 million in 2023, then climbed by 1.62% to $145.9 million in 2024, then jumped by 61.54% to $235.7 million in 2025, then declined by 1.28% to $232.7 million in 2026.
• The last three Receivables - Net figures came in at $232.7 million (Q1 2026), $235.7 million (Q4 2025), and $203.7 million (Q3 2025), per Business Quant data.